In this co-published analysis, Sunstein’s Lisa M Tittemore and Natalie A Salas dive into the metaverse and explore what NFTs could mean for pharmaceutical brands.
The push to digital/virtual is inexorable. The expanding digital/virtual world opens up many new innovations and developments, and one of the latest generating significant buzz is NFTs (non-fungible tokens). We have written about NFTs in connection with other kinds of IP (copyright and patent) Here, we discuss the implications of these new digital assets for trademarks and assess some of the opportunities and challenges of NFT use for brand owners, and for pharmaceutical brands in particular.
Read more here.